Skip to main content
PMC home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2010 Jul 13;33(7):400–405. doi: 10.1002/clc.20760

Use of Guideline‐Recommended Therapies for Heart Failure in the Medicare Population

Lisa D DiMartino 1, Alisa M Shea 1, Adrian F Hernandez 1,2, Lesley H Curtis 1,2,✉
PMCID: PMC3740389  NIHMSID: NIHMS231486  PMID: 20641116

Abstract

Background

Most information about the use of guideline‐recommended therapies for heart failure reflects what occurred at discharge after an inpatient stay.

Hypothesis

Using a nationally representative, community‐dwelling sample of elderly Medicare beneficiaries, we examined how the use of angiotensin‐converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and β‐blockers has changed and factors associated with their use.

Methods

Using data from the Medicare Current Beneficiary Survey cost and use files matched with Medicare claims data, we identified beneficiaries for whom a diagnosis of heart failure was reported between January 1, 2000, and December 31, 2004. Data on medications prescribed during the year of cohort entry were based on patient self‐report. We used multivariable logistic regression to explore relationships between the use of ACE inhibitors/ARBs and β‐blockers and patient demographic characteristics.

Results

From 2000 through 2004, the use of ARBs increased from 12% to 19%, and the use of β‐blockers increased from 30% to 41%. The use of ACE inhibitors remained constant at 45%. Beneficiaries who reported having prescription drug insurance coverage were 32% more likely than other beneficiaries to have filled a prescription for an ACE inhibitor or ARB and 26% more likely to have filled a prescription for a β‐blocker.

Conclusions

Although the use of guideline‐recommended therapies for heart failure has increased, it remains suboptimal. Copyright © 2010 Wiley Periodicals, Inc.

Full Text

The Full Text of this article is available as a PDF (119.7 KB).

REFERENCES

  • 1. Curtis LH, Whellan DJ, Hammill BG, et al. Incidence and prevalence of heart failure in elderly persons, 1994–2003. Arch Intern Med 2008; 168: 418–424. [DOI] [PubMed] [Google Scholar]
  • 2. Lloyd‐Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics—2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee [published correction appears in Circulation. 2009;119:e182]. Circulation 2009; 119: 480–486. [DOI] [PubMed] [Google Scholar]
  • 3. Curtis LH, Greiner MA, Hammill BG, et al. Early and long‐term outcomes of heart failure in elderly persons, 2001–2005. Arch Intern Med 2008; 168: 2481–2488. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Setoguchi S, Levin R, Winkelmayer WC. Long‐term trends of angiotensin‐converting enzyme inhibitor and angiotensin‐receptor blocker use after heart failure hospitalization in community‐dwelling seniors. Int J Cardiol 2008; 125: 172–177. [DOI] [PubMed] [Google Scholar]
  • 5. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112: e154–e235. [DOI] [PubMed] [Google Scholar]
  • 6. Hernandez AF, Hammill BG, O'Connor CM, et al. Clinical effectiveness of beta‐blockers in heart failure: findings from the OPTIMIZE‐HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure) registry. J Am Coll Cardiol 2009; 53: 184–192. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Butler J, Arbogast PG, Daugherty J, et al. Outpatient utilization of angiotensin‐converting enzyme inhibitors among heart failure patients after hospital discharge. J Am Coll Cardiol 2004; 43: 2036–2043. [DOI] [PubMed] [Google Scholar]
  • 8. Masoudi FA, Rathore SS, Wang Y, et al. National patterns of use and effectiveness of angiotensin‐converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. Circulation 2004; 110: 724–731. [DOI] [PubMed] [Google Scholar]
  • 9. Berger AK, Duval S, Manske C, et al. Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease. Am Heart J 2007; 153: 1064–1073. [DOI] [PubMed] [Google Scholar]
  • 10. Jencks SF, Cuerdon T, Burwen DR, et al. Quality of medical care delivered to Medicare beneficiaries: a profile at state and national levels. JAMA 2000; 284: 1670–1676. [DOI] [PubMed] [Google Scholar]
  • 11. Masoudi FA, Baillie CA, Wang Y, et al. The complexity and cost of drug regimens of older patients hospitalized with heart failure in the United States, 1998–2001. Arch Intern Med 2005; 165: 2069–2076. [DOI] [PubMed] [Google Scholar]
  • 12. Adler GS. A profile of the Medicare Current Beneficiary Survey. Health Care Financ Rev 1994; 15: 153–163. [PMC free article] [PubMed] [Google Scholar]
  • 13. Kamal‐Bahl S, Stuart BC, Beers MH. National trends in and predictors of propoxyphene use in community‐dwelling older adults. Am J Geriatr Pharmacother 2005; 3: 186–195. [DOI] [PubMed] [Google Scholar]
  • 14. Moxey ED, O'Connor JP, Novielli KD, et al. Prescription drug use in the elderly: a descriptive analysis. Health Care Financ Rev 2003; 24: 127–141. [PMC free article] [PubMed] [Google Scholar]
  • 15. Arday SL, Arday DR, Monroe S, et al. HCFA's racial and ethnic data: current accuracy and recent improvements. Health Care Financ Rev 2000; 21: 107–116. [PMC free article] [PubMed] [Google Scholar]
  • 16. Fonarow GC, Abraham WT, Albert NM, et al. Influence of a performance‐improvement initiative on quality of care for patients hospitalized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE‐HF). Arch Intern Med 2007; 167: 1493–1502. [DOI] [PubMed] [Google Scholar]
  • 17. Jackson JE, Doescher MP, Saver BG, et al. Prescription drug coverage, health, and medication acquisition among seniors with one or more chronic conditions. Med Care 2004; 42: 1056–1065. [DOI] [PubMed] [Google Scholar]
  • 18. Tjia J, Briesacher BA. Prescription drug benefits and use of guideline recommended medications by elderly Medicare beneficiaries with diabetes mellitus. J Am Geriatr Soc 2008; 56: 1879–1886. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Steinman MA, Sands LP, Covinsky KE. Self‐restriction of medications due to cost in seniors without prescription coverage. J Gen Intern Med 2001; 16: 793–799. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.The Henry J. Kaiser Family Foundation. Medicare: A Primer, 2009. http://www.kff.org/medicare/7615.cfm. Accessed October 28, 2009.
  • 21. Hudson N. Changes in drug utilization for seniors without prior prescription drug insurance. Find Brief 2009; 12: 1–3. [PubMed] [Google Scholar]
  • 22. Kramer JM, Chen AY, Hammill BG, et al. Time trends and factors associated with outpatient beta‐blocker use in patients with heart failure or left ventricular dysfunction. Circulation 2004; 104: e231–e184. [Google Scholar]
  • 23. Kramer JM, Curtis LH, Dupree CS, et al. Comparative effectiveness of beta‐blockers in elderly patients with heart failure. Arch Intern Med 2008; 168: 2422–2428. [DOI] [PubMed] [Google Scholar]
  • 24. Elam L. Dual Eligibles. The Henry J. Kaiser Family Foundation. http://www.kaiseredu.org/tutorials/Duals/Duals.html. Published 2006. Accessed September 10, 2009.
  • 25. Setoguchi S, Glynn RJ, Avorn J, et al. Ten‐year trends of cardiovascular drug use after myocardial infarction among community‐dwelling persons > or = 65 years of age. Am J Cardiol 2007; 100: 1061–1067. [DOI] [PubMed] [Google Scholar]
  • 26. McMurray J, Cohen‐Solal A, Dietz R, et al. Practical recommendations for the use of ACE inhibitors, beta‐blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice. Eur J Heart Fail 2005; 7: 710–721. [DOI] [PubMed] [Google Scholar]
  • 27. Newby LK, LaPointe NM, Chen AY, et al. Long‐term adherence to evidence‐based secondary prevention therapies in coronary artery disease. Circulation 2006; 113: 203–212. [DOI] [PubMed] [Google Scholar]
  • 28. Federman AD, Adams AS, Ross‐Degnan D, et al. Supplemental insurance and use of effective cardiovascular drugs among elderly Medicare beneficiaries with coronary heart disease. JAMA 2001; 286: 1732–1739. [DOI] [PubMed] [Google Scholar]
  • 29. Choudhry NK, Setoguchi S, Levin R, et al. Trends in adherence to secondary prevention medications in elderly post‐myocardial infarction patients. Pharmacoepidemiol Drug Saf 2008; 17: 1189–1196. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES